Role of melatonin, serotonin 2B, and serotonin 2C receptors in modulating the firing activity of rat dopamine neurons

Journal of Psychopharmacology

Volumn 28, Issue 2, 2014, Pages 162-167

  Chenu, Franck ^a   Shim, Stacey ^a   El Mansari, Mostafa ^a   Blier, Pierre ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

antidepressant; electrophysiology; melatonin; serotonin 2B receptor; serotonin 2C receptor; Ventral tegmental area

Indexed keywords

6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; DOPAMINE; LY 266097; MELATONIN; MELATONIN RECEPTOR; NORADRENALIN; SEROTONIN; SEROTONIN 2 ANTAGONIST; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DORSAL RAPHE NUCLEUS; IN VIVO STUDY; LOCUS CERULEUS; MALE; MONOAMINERGIC SYSTEM; NERVE CELL MEMBRANE POTENTIAL; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; UPREGULATION; VENTRAL TEGMENTUM;

ANTIDEPRESSANT; ELECTROPHYSIOLOGY; MELATONIN; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; VENTRAL TEGMENTAL AREA;

AMINOPYRIDINES; ANIMALS; DOPAMINERGIC NEURONS; INDOLES; LOCUS COERULEUS; MALE; MELATONIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; VENTRAL TEGMENTAL AREA;

EID: 84892944595     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113510071     Document Type: Article

References (40)

1. Al-Ghoul WM, Herman MD, Dubocovich ML. Melatonin receptor subtype expression in human cerebellum. Neuroreport. 1998 ; 9: 4063-4068 (Pubitemid 29030689)
2. Auclair AL, Cathala A, Sarrazin F, et al. The central serotonin 2B receptor: A new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. J Neurochem. 2010 ; 114: 1323-1332
3. Bertaina-Anglade V, la Rochelle CD, Boyer PA, et al. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmaco. 2006 ; 17: 703-713
4. Blier P, Zigman D, Blier J. On the safety and benefits of repeated intravenous injections of ketamine for depression. Biol Psychiatry. 2012 ; 72: e11-12
5. Castillo Romero JL, Vives Montero F, Acuna Castroviejo D. Paradoxical effects of melatonin on spontaneous neuronal activity in the striatum of sham-operated and pinealectomized rats. J Pineal Res. 1992 ; 12: 149-154
6. Chenu F, El Mansari M, Blier P. Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area. Int J Neuropsychopharmacol. 2009 ; 12: 475-485
7. Chenu F, El Mansari M, Blier P. Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain. Neuropsychopharmacology. 2013 ; 38: 275-284
8. Ciesielczyk K, Pracka D, Pracki T, et al. Changes of sleep quality and mood disorders under the influence of phototherapy in patients with seasonal affective disorder SAD. Psychiatr Pol. 2004 ; 38: 1105-1114 (Pubitemid 40379120)
9. De Bodinat C, Guardiola-Lemaitre B, Mocaer E, et al. Agomelatine, the first melatonergic antidepressant: Discovery, characterization and development. Nat Rev Drug Discov. 2010 ; 9: 628-642
10. Dekeyne A, Millan MJ. Discriminative stimulus properties of the selective and highly potent alpha2-adrenoceptor agonist, S18616, in rats: mediation by the alpha2A subtype, and blockade by the atypical antidepressants, mirtazapine and mianserin. Neuropharmacology. 2006 ; 51: 718-726 (Pubitemid 44376400)
11. DeVries MW, Peeters FP. Melatonin as a therapeutic agent in the treatment of sleep disturbance in depression. J Nerv Ment Dis. 1997 ; 185: 201-202 (Pubitemid 27508673)
12. Di Giovanni G, De Deurwaerdere P, Di Mascio M, et al. Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: A combined in vivo electrophysiological and microdialysis study. Neuroscience. 1999 ; 91: 587-597 (Pubitemid 29193268)
13. Di Matteo V, Di Giovanni G, Di Mascio M, et al. SB 242084, a selective serotonin 2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology. 1999 ; 38: 1195-1205 (Pubitemid 29292408)
14. Diaz SL, Doly S, Narboux-Neme N, et al. 5-HT(2B) receptors are required for serotonin-selective antidepressant actions. Mol Psychiatry. 2012 ; 17: 154-163
15. Dolberg OT, Hirschmann S, Grunhaus L. Melatonin for the treatment of sleep disturbances in major depressive disorder. Am J Psychiatry. 1998 ; 155: 1119-1121 (Pubitemid 28357744)
16. Doly S, Bertran-Gonzalez J, Callebert J, et al. Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice. PLoS One. 2009 ; 4: e7952
17. Doly S, Valjent E, Setola V, et al. Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J Neurosci. 2008 ; 28: 2933-2940 (Pubitemid 351398883)
18. Dominguez-Lopez S, Mahar I, Bambico FR, et al. Short-term effects of melatonin and pinealectomy on serotonergic neuronal activity across the light-dark cycle. J Psychopharmacol. 2012 ; 26: 830-844
19. Duxon MS, Flanigan TP, Reavley AC, et al. Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system. Neuroscience. 1997 ; 76: 323-329 (Pubitemid 27008463)
20. Esteban S, Garau C, Aparicio S, et al. Chronic melatonin treatment and its precursor L-tryptophan improve the monoaminergic neurotransmission and related behavior in the aged rat brain. J Pineal Res. 2010 ; 48: 170-177
21. Gobert A, Rivet JM, Lejeune F, et al. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat. Synapse. 2000 ; 36: 205-221 (Pubitemid 30252995)
22. Hajos M, Gartside SE, Villa AE, et al. Evidence for a repetitive (burst) firing pattern in a sub-population of 5-hydroxytryptamine neurons in the dorsal and median raphe nuclei of the rat. Neuroscience. 1995 ; 69: 189-197
23. Hale A, Corral RM, Mencacci C, et al. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: A randomized, double-blind study. Int Clin Psychopharmacol. 2010 ; 25: 305-314
24. Jenck F, Bos M, Wichmann J, et al. The role of 5-HT2C receptors in affective disorders. Expert Opin Investig Drugs. 1998 ; 7: 1587-1599 (Pubitemid 28451656)
25. Jensen NH, Cremers TI, Sotty F. Therapeutic potential of 5-HT2C receptor ligands. ScientificWorldJournal. 2010 ; 10: 1870-1885
26. Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, double-blind comparison with sertraline. J Clin Psychiatry. 2010 ; 71: 109-120
27. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006 ; 16: 93-100 (Pubitemid 43145814)
28. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: Randomized, double-blind comparison with venlafaxine. J Clin Psychiatry. 2007 ; 68: 1723-1732 (Pubitemid 350247502)
29. Mantovani M, Pertile R, Calixto JB, et al. Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: Evidence for involvement of N-methyl-D-aspartate receptors and the L-arginine-nitric oxide pathway. Neurosci Lett. 2003 ; 343: 1-4 (Pubitemid 36577198)
30. Millan MJ, Brocco M, Gobert A, et al. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: Role of 5-HT2C receptor blockade. Psychopharmacology (Berl). 2005 ; 177: 448-458
31. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003 ; 306: 954-964 (Pubitemid 37025301)
32. Millan MJ, Gobert A, Rivet JM, et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: A comparison with citalopram. Eur J Neurosci. 2000 ; 12: 1079-1095 (Pubitemid 30168787)
33. Molteni R, Calabrese F, Pisoni S, et al. Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration. World J Biol Psychiatry. 2010 ; 11: 148-153
34. Naranjo-Rodriguez EB, Prieto-Gomez B, Reyes-Vazquez C. Melatonin modifies the spontaneous multiunit activity recorded in several brain nuclei of freely behaving rats. Brain Res Bull. 1991 ; 27: 595-600
35. Overstreet DH, Pucilowski O, Retton MC, et al. Effects of melatonin receptor ligands on swim test immobility. Neuroreport. 1998 ; 9: 249-253 (Pubitemid 28081397)
36. Racagni G, Riva MA, Molteni R, et al. Mode of action of agomelatine: Synergy between melatonergic and 5-HT2C receptors. World J Biol Psychiatry. 2011 ; 12: 574-587
37. Savaskan E, Wirz-Justice A, Olivieri G, et al. Distribution of melatonin MT1 receptor immunoreactivity in human retina. J Histochem Cytochem. 2002 ; 50: 519-526
38. Uz T, Arslan AD, Kurtuncu M, et al. The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system. Brain Res Mol Brain Res. 2005 ; 136: 45-53 (Pubitemid 40704608)
39. Valenti O, Lodge DJ, Grace AA. Aversive stimuli alter ventral tegmental area dopamine neuron activity via a common action in the ventral hippocampus. J Neurosci. 2011 ; 31: 4280-4289
40. Zisapel N, Egozi Y, Laudon M. Inhibition of dopamine release by melatonin: Regional distribution in the rat brain. Brain Res. 1982 ; 246: 161-163 (Pubitemid 12048856)